Andrew J.  Grethlein net worth and biography

Andrew Grethlein Biography and Net Worth

xecutive Vice President, Chief Operating Officer of Geron

Previously, he served as our Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as our Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology-oriented biopharmaceutical company, where he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions.

Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a non-profit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon’s Rock Early College, his B.S. in biology from Bates College and his M.S. and Ph.D. in chemical engineering from Michigan State University.

How do I contact Andrew J. Grethlein?

The corporate mailing address for Dr. Grethlein and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at [email protected]. Learn More on Andrew J. Grethlein's contact information.

Has Andrew J. Grethlein been buying or selling shares of Geron?

Andrew J. Grethlein has not been actively trading shares of Geron during the last ninety days. Learn More on Andrew J. Grethlein's trading history.

Who are Geron's active insiders?

Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.

Andrew J. Grethlein Insider Trading History at Geron

See Full Table

Andrew J. Grethlein Buying and Selling Activity at Geron

This chart shows Andrew J. Grethlein's buying and selling at Geron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Geron Company Overview

Geron logo
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $1.67
Low: $1.66
High: $1.79

50 Day Range

MA: $1.62
Low: $1.40
High: $1.95

2 Week Range

Now: $1.67
Low: $1.04
High: $2.01

Volume

16,567,749 shs

Average Volume

19,557,790 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67